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Background:  Venous thromboembolism (VTE) is a common disease with a problematic treatment. The results from the JUPITER trial 
indicated that statins might reduce the risk of VTE.
methods:  We conducted a systematic review and meta-analyses of published and unpublished data to assess the effect of statins on 
VTE and bleeding. Medline, EMBASE and CENTRAL were searched in October 2013. The authors of relevant studies were contacted 
for retrieval data on total VTE, pulmonary embolism, deep vein thrombosis and bleeding-events. The resulting data was pooled in meta-
analyses according to a pre-specified protocol.
results:  30 studies with 147,032 patients were included in our analyses. The main meta-analysis, including all studies, did not show a 
significant effect of statins on VTE, compared to control, RR 0.91 95%CI (0.82-1.02). Pre-planned subgroup analyses showed a significant 
risk reduction with statins in studies with low baseline usage of Acetylsalicylic acid (ASA), RR 0.68 95% CI (0.53-0.88). Also, a significant 
reduction of VTE was seen in studies where low-density lipoprotein (LDL)-cholesterol was lowered more than 1mmol/l RR 0.77 95% CI 
(0.61-0.96) and in studies with type 2 statins (Rosuvastatin, Atorvastatin, Fluvastatin) RR 0.84 95% CI(0.71-0.98). Due to insufficient data 
we could not produce results regarding bleeding-risks.
conclusion:  In certain groups, statins appear to reduce the risk of venous thromboembolism. This was evident in subgroup analyses 
based on trials with low ASA-usage, large LDL-lowering or type 2 statins. The relationship between these parameters needs to be further 
investigated.
